Relationship between initial dose, dose intensity, and survival in unresectable pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid
Reduced starting dose and RDI <80% were not associated with inferior survival, suggesting that individualized dose modification may be feasible, and future prospective studies are warranted to refine NFF dosing strategies.
Abstract
While nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard second-line regimen for unresectable pancreatic cancer (uPC) after gemcitabine-based therapy, the effects of initial dosing and relative dose intensity (RDI) in routine practice are unclear. We retrospectively analyzed 161 patients (median age 67 years; 55% male) with uPC treated with NFF at 20 Japanese institutions (June 2020–May 2021), comparing standard vs. reduced starting dose and RDI ≥80% vs. <80%. Overall survival (OS) was 8.1 vs. 8.8 months for standard vs. reduced dose (
p
= 0.47; hazard ratio [HR], 1.15) and 7.5 vs. 9.2 months for RDI ≥80% vs. <80% (
p
= 0.39; HR, 0.85). Progression-free survival (PFS) was 3.4 vs. 3.2 months (
p
= 0.43) and 2.8 vs. 4.4 months (
p
= 0.13), respectively, with similar response and disease control rates. Anemia, thrombocytopenia, and vomiting occurred more frequently in patients administered the standard starting dose, whereas severe non-hematologic adverse events were more frequently observed for RDI <80%. Reduced starting dose and RDI <80% were not associated with inferior survival, suggesting that individualized dose modification may be feasible. Future prospective studies are warranted to refine NFF dosing strategies.
OBJECTIVE
To compare lenvatinib (LEN) and atezolizumab plus bevacizumab (Atezo + Bev) as first-line therapy in super-older adults (≥80 years) with hepatocellular carcinoma (HCC) and evaluate whether early relative dose intensity (RDI) is associated with outcomes.
METHODS
This retrospective cohort study included super...
Masamichi Kimura, K. Nishikawa, Jun Imamura et al.· European Journal of Gastroen...· 0 citations
KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metasta...
S. Shi, Miao-Yan Wei, N. Du et al.· Cancer Cell· 2 citations
OBJECTIVE
To evaluate the association between bevacizumab relative dose intensity (RDI) and first-line treatment outcomes in advanced epithelial ovarian cancer.
METHODS
We retrospectively analyzed 72 patients treated with first-line bevacizumab plus paclitaxel-platinum chemotherapy between January 2019 and September...
Li-Ming Zhang, Mei-Lin Chen, Zhen Yang et al.· Journal of Gynecologic Oncol...· 0 citations
The benefit of adding programmed cell death protein 1 (PD-1) blockade to hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib for unresectable hepatocellular carcinoma remains uncertain. This single-center retrospective cohort study included 373 patients. After propensity score matching, 107 patients treated w...
Hai-Dong Yu, Cun-Kai Ma, C. Yangdan et al.· Journal of chemotherapy· 0 citations
Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastr...
S. Rha, L. Wyrwicz, P. Yanez et al.· ESMO Open· 1 citation· ⚡1
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.